Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company distributes and sells plant-based pharmaceutical products.
| Line item | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|
| Net Cash from Operating Activities | 45 | 832 | 0 | +1748.8% |
| Net Cash used in Investing Activities | 179 | 142 | 0 | -20.7% |
| Free Cash Flow (OCF − Capex proxy) | 134 | 690 | 0 | nmf |
| Net Change in Cash (before FX) | 134 | 690 | 0 | nmf |
| Effect of FX on Cash | 110 | 32 | 0 | -71.1% |
| Net Change in Cash (incl. FX) | 243 | 658 | 0 | nmf |
| Cash at Beginning of Year | 378 | 135 | 0 | -64.4% |
| Cash at End of Year | 135 | 793 | 0 | +488.4% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →